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Rationale
VR588 is a selective pan-JAK inhibitor that
demonstrates potent activity in a series of
in-vitro models (see associated poster).
Viral infection is an important trigger of
airway disease exacerbation. The JAK-
STAT pathway is activated by viral
infection in asthmatic and COPD patients
and is associated with the related
inflammatory process. This study was
designed to compare the effects of
inhaled and oral VR588 in a murine model
of viral lung inflammation.
Methods
The viral RNA mimetic Poly(I:C)(1mg/ml)
was administered intranasally to male
BALB/c mice 1 hour after VR588
administration and again 16 hours later.
VR588 was given at intranasal doses of 1.5,
7.5 and 15mg/kg and at an oral dose of
15mg/kg (n=6 per group). Lung tissue and
bronchoalveolar lavage (BAL) fluid was
harvested 40 hours after the initial
Poly(I:C) challenge. Inflammatory cell
count from BAL fluid was determined
using FACS analysis; JAK-STAT activation
(pSTAT1, 3 & 5) was measured by ELISA
and BAL inflammatory cytokines by
Luminex immunoassay. Fluticasone
propionate (intranasal dose of 1.5 mg/kg)
and tofacitinib (oral dose of 15 mg/kg)
were employed as relevant comparators.
Poly(I:C) increased total BAL cell count
which was reduced in a dose-related
manner by intranasal VR588. In contrast,
oral administration of VR588 was
ineffective.
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Intranasal VR588 attenuated the
expression of poly(I:C)-induced BAL
eotaxin, MIP-1α & β, IP-10, KC, TNF-α and
MCP-1 in a dose-related manner to a
similar extent as FP and ToF. VR588 did
not significantly attenuate VEGF and
RANTES.
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Results III
pSTAT1 and pSTAT5 (Fig 3A & C), but not
pSTAT3 (Fig 3B), were increased by Poly(I:C)
treatment and attenuated by VR588.
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Conclusions
VR588 attenuated Poly(I:C)-induced
inflammatory cell accumulation, cytokine
production and activation of STAT
signalling pathways and was more
effective by the inhaled versus the oral
route.
This supports the concept that JAK
inhibition may be a useful strategy for the
treatment viral exacerbation in airway
disease.
Further studies evaluating the VR588 via
the inhaled route in-vivo profile post
repeat dose exposure are justified.
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Figure 3. The effect of Poly(I:C) and intranasal (i.n.)
and oral (p.o.) RV588 on (A) pSTAT1, (B) pSTAT3 and
(C) pSTAT5 activation in murine lung. Fluticasone
propionate (FP) was used as a relevant
comparators. **p<0.01 vs. saline group, #p<0.05,
##p<0.01 vs. Poly(I:C) group, Mann Whitney test.
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Figure 1. The effect of Poly(I:C) and intranasal (i.n.)
and oral (p.o.) VR588 on total BAL cell count.
Fluticasone propionate (FP) and Tofacitinib (ToF)
were used as relevant comparators. **p<0.01 vs.
saline group, #p<0.05, ##p<0.01 vs. Poly(I:C) group,
Mann Whitney test.
Figure 2. The effect of poly(I:C) and intranasal (i.n.)
and oral (p.o.) RV588 on BAL mediator expression.
Fluticasone propionate (FP) and Tofacitinib (ToF)
were used as a relevant comparators. **p<0.01 vs.
saline group, #p<0.05, ##p<0.01 vs. Poly(I:C) group,
Mann Whitney test.
Table 1. List of inflammatory mediators increased by
Poly(I:C) treatment in murine lung.
MCP-1
TNFα
KC
IP-10
MIP-1β
MIP-1α
Eotaxin
